Thursday, October 6, 2022

India’s first HPV vax against cervical cancer launched

The Centre on Thursday announced the “Cervavac”, India’s first indigenously-developed vaccine for prevention of cervical cancer, will be launched in the next few months and will be available in the price range of Rs 200-Rs 400.
Cervical cancer ranks as the 2nd most prevalent cancers in India and accounts for nearly one-fourth of the world’s cervical cancer deaths despite being largely preventable. As per current estimates, every year, approximately 1.25 lakh women are diagnosed with cervical cancer, and over 75,000 die from the disease in India, and 83 per cent of invasive cervical cancers are attributed to HPVs 16 or 18 in India, and 70 per cent of cases worldwide.
Announcing the scientific completion of the quadrivalent Human Papilloma Virus (qHPV) vaccine in presence of Adar C. Poonawalla, CEO, Serum Institute of India and other prominent scientists and dignitaries, Union Science & Technology Minister Jitendra Singh said that this affordable and cost-effective vaccine marks an important day for the DBT and the BIRAC.
The first indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) vaccine will be launched in few months, Poonawalla said, adding that the vaccine will be available to the people in an affordable price range of Rs 200-400.

SourceIANS